All Stories

Kiniksa adds to Sjögren's exodus with trial termination, axes AstraZeneca asset

Kiniksa Pharmaceuticals is stopping development of a midphase autoimmune asset and returning a drug candidate to AstraZeneca as it doubles down on its cardiovascular disease pipeline.

Feb 26, 2025 - 11:45
 0
Kiniksa adds to Sjögren's exodus with trial termination, axes AstraZeneca asset
Kiniksa Pharmaceuticals is stopping development of a midphase autoimmune asset and returning a drug candidate to AstraZeneca as it doubles down on its cardiovascular disease pipeline.
Read More

Tags:

Previous Article

Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocke...

Next Article

Human medicines European public assessment report (EPAR): Eklira Genuair, aclidi...

Related Posts

Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal

Teleflex plays musical chairs, plans company split amid...

Feb 27, 2025  0

Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%

Eli Lilly buys Organovo's FXR program for $10M, sending...

Feb 26, 2025  0

Genentech archives diversity reports amid site update, examines ‘potential implications of executive orders’

Genentech archives diversity reports amid site update, ...

Feb 13, 2025  0